DL-Norleucine
CAS RN: 616-06-8
| Solubility in 3M-HCl | Colorless & clear (c=5) |
| Loss on drying | Not more than 0.3% |
| Residue on ignition (as sulfate) | Not more than 0.1% |
| Chloride (Cl) | Not more than 0.02% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 10μg) |
| Assay | 98.5%～101.0% |
We are professional DL-Norleucine manufacturer and H-DL-Nle-OH supplier in China, We offer quality 2-aminohexanoic acid you can fully trust, also we have India factory and producer of DL-Norleucine,Pls send inquiry of Norleucine,L CAS:616-06-8 to info@nbinno.com if you have any interests, thank you!
Related News: European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.1-Bromo-2,3-epoxypropane European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.1,7-Dibromoheptane CAS:4549-31-9 Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.2,4-Dichlorophenylboronic acid CAS:68716-47-2 As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.
